1A00210

3′-(N,N-Didemethyl)-3′-N-Formylazithromycin

Pharmaceutical Analytical Impurity (PAI)

• Synonyme(s) : (N-((2S,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4- methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan11-yl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-4-yl)formamide), ((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(formylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa6-azacyclopentadecan-15-one), (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-formamido-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6- azacyclopentadecan-15-one)
• Formule empirique (notation de Hill): C₃₇H₆₈N₂O₁₃
• Numéro CAS: 765927-71-7
• Poids moléculaire : 748.94
• Code UNSPSC : 41116100
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: pharmaceutical analytical impurity (PAI)
• Agence: USP
• Famille d'API: azithromycin
• Fabricant/nom de marque: USP
• Application(s): pharmaceutical
• Format: neat
• Température de stockage: 2-8°C

Description

Description générale

3′-(N,N-Didemethyl)-3′-N-Formylazithromycin is a USP Pharmaceutical Analytical Impurity (PAI).

USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.

Associated Drug Substance: Azithromycin

Therapeutic Area: Antibiotics.

For more information about this PAI, visit here.

Application

3′-(N,N-Didemethyl)-3′-N-Formylazithromycin (USP PAI) is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.

Caractéristiques et avantages

USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Autres remarques

Sales restrictions may apply.

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable